Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics (GRTX)
OTHER OTC:GRTX
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.05
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$3.55M
Enterprise Value-$926.27K
Total Cash (Recent Filing)$4.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,462,390
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.21
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.24
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash Burn In 2024The sharp improvement in operating cash flow and free cash flow in 2024 materially extends runway versus 2023 levels. This durable reduction in cash burn reflects tighter cost control and improved cash conversion, lowering near-term refinancing risk and improving strategic optionality.
Focused Clinical-stage NicheA clear, specialized focus on protecting normal tissues during radiotherapy targets a persistent unmet medical need. This structural niche sustains long-term demand and can attract strategic partnerships or licensing, creating durable optionality even absent near-term commercial revenue.
Asset Sale Shifted Liabilities To BuyerThe sale of dismutase mimetic assets and transfer of associated liabilities to Biossil is a structural balance-sheet event. By offloading obligations (including Blackstone-related ones), Galera reduces contingent risks and financing pressure, materially improving solvency profile going forward.
Bears Say
Deeply Negative Equity And Large Debt SpikeNegative equity combined with a step-change in leverage sharply raises solvency and refinancing risk. With assets of only ~$10M, the company has limited collateral or flexibility, making sustained operations vulnerable to credit market access and adverse covenant or liquidity shocks.
No Revenue And Ongoing Operating LossesAbsence of product revenue means the business is entirely dependent on financing or asset transactions to fund R&D and operations. Persistent material losses erode flexibility and make long-term viability contingent on successful partnerships, asset sales, or new financing.
Negative Free Cash Flow, Reliance On External FinancingAlthough cash burn improved, free cash flow remains negative, implying ongoing external funding needs. This structural dependence increases dilution or debt risk, and sustained negative FCF limits the company's ability to invest in development without recurring financing events.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.05 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $3.55M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 75,462,390 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
10.40% Insiders
<0.01% Mutual Funds
3.90% Other Institutional Investors
85.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---